Approval · Notice of Compliance 21820 · 2019
CIPRO: Notice of Compliance 21820
Issued February 1, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21820
- Date
- February 1, 2019
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- To update the Product Monograph with new Safety Information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CIPRO | Not yet assigned | — |
| CIPRO ORAL SUSPENSION | Not yet assigned | — |
Medicinal ingredients
- CIPROFLOXACIN 500 MG per TAB
- CIPROFLOXACIN 750 MG per TAB
- CIPROFLOXACIN 250 MG per TAB
- CIPROFLOXACIN 10 G per 100ML